Chiome Bioscience Inc. (TYO:4583)

Japan · Delayed Price · Currency is JPY

86.00

+1.00 (1.18%)

Aug 27, 2026, 1:47 PM JST

-39.44% (1Y)

Market Cap	6.71B -30.6%
Revenue (ttm)	615.15M -20.0%
Net Income	-925.73M
EPS	-13.12
Shares Out	78.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148,100
Open	85.00
Previous Close	85.00
Day's Range	84.00 - 87.00
52-Week Range	65.00 - 142.00
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Chiome Bioscience

Chiome Bioscience Inc. engages in the research and development of antibody drugs in Japan, Singapore, and internationally. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib system, a monoclonal antibody production technology that uses chicken immune cells to produce antibodies for drug discovery research. It also develops drugs under Phase I clinical trial, including ADCT-701, a humanized anti-dlk1 antibody for the treatment of solid tumors; CBA-1205, a humanized afucosylated anti... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2005

Employees 53

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4583

Full Company Profile

Financial Performance

In 2025, Chiome Bioscience's revenue was 593.29 million, a decrease of -24.02% compared to the previous year's 780.81 million. Losses were -982.78 million, -3.72% less than in 2024.

Financial Statements